Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifestyle plan aims to boost Well-Being in lymphoma survivors

NCT ID NCT05934084

Symptom relief Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 years. The study will compare those who receive the lifestyle plan to those who do not, measuring changes in well-being and daily functioning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 552 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-50 at initial treatment; * Diagnosis of classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL) or Primary mediastinal large B-cell lymphoma (PMBCL); * Patients in Complete Remission (CR) after first-line therapy \[ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin , cyclophosphamide, vincristine, procarbazine and prednisone) or ABVD-BEACOPP Pet-2 guided treatment for cHL; R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone) for DLBCL; R-CHOP or R-DA-EPOCH (rituximab- Dose Adapted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for PMBCL); * Patients in remission for a minimum 3 years since the last treatment and a maximum of 10 years; * Cumulative doxorubicin/ adriamycin dose received of at least 200 mg/mq (4 cycles of chemotherapy); * Availability echocardiogram (ECG) and 2D-STE-echocardiography (Two-dimensional speckle strain echocardiography) performed no later than three months prior to enrollment; * Signature of a written informed consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate voluntarily in the study. Exclusion Criteria: * Diagnosis of secondary cancer at baseline, except non-melanoma skin cancers and adequately treated cone-biopsied in situ carcinoma of the cervix; * Second line chemotherapy of stem cell transplant; * Not able to perform physical activity; * Grade \>/=3 neuropathy; * Vertebral fractures or stenosis of the vertebral canal; other bone fracture; * Cardiovascular disease: arrhythmia \>/= grade 2, hypertension \>/ grade 2, left ventricular dysfunction \>/= grade 2 pericardial disease/effusion any grade, myocarditis any grade, pulmonary hypertension any grade, restrictive cardiomyopathy any grade valvular hearth disease \>/= grade 2, right ventricular dysfunction \>/= grade 2; * Venous thromboembolism or arterial thrombosis during last 6 months; * Hemorrhage/ bleeding \>/= grade 2 during last 6 months; * Chronic lymphedema (arms and/ or limbs); * Rheumatic disease or inflammatory bowel disease in systemic treatment; * Any pleural effusion; * If female, the patient is pregnant; * Unwilling to comply to all required visits and procedures for the duration of study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma diffuse large B-cell lymphoma Motor Activity primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma Diffuse large B-cell lymphoma (DLBCL) Primary mediastinal large B-cell lymphoma (PMBCL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    39 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.R. "San Carlo" - U.O. Ematologia

    NOT_YET_RECRUITING

    Potenza, Italy

  • A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria

    RECRUITING

    Torino, Italy

  • AO Sant'Andrea - Ematologia

    RECRUITING

    Roma, Italy

  • AOU G. Martino - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Messina, Italy

  • AOU G. Martino - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Pisa, Italy

  • AOU Maggiore della Caritа di Novara - SCDU Ematologia

    RECRUITING

    Novara, Italy

  • AOU Policlinico Giaccone - Ematologia

    RECRUITING

    Palermo, Italy

  • AOU di Padova - Ematologia

    RECRUITING

    Padova, Italy

  • AOU di Sassari - Ematologia

    RECRUITING

    Sassari, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

    RECRUITING

    Milan, Italy

  • ASST Ovest Milanese - Legnano - U.O.C. Ematologia Ospedale Civile di Legnano

    RECRUITING

    Legnano, Italy

  • ASST Spedali Civili di Brescia - Ematologia

    RECRUITING

    Brescia, Italy

  • Ancona - AOU Ospedali Riuniti - Clinica di Ematologia

    RECRUITING

    Ancona, Ancona, Italy

  • Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia

    RECRUITING

    Catania, Italy

  • Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati

    RECRUITING

    Aviano, Aviano, Italy

  • Azienda Ospedaliera Universitaria Careggi - Unitа funzionale di Ematologia

    RECRUITING

    Florence, Italy

  • Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Emtologia

    RECRUITING

    Catania, Italy

  • Azienda Ospedaliero-Universitaria Policlinico di Modena - U.O. Oncologia

    RECRUITING

    Modena, Italy

  • Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

    RECRUITING

    Reggio Emilia, Italy

  • I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1

    RECRUITING

    Padova, Italy

  • IEO Istitito Europeo di Oncologia - Divisione Ematoncologia

    RECRUITING

    Milan, Italy

  • Istituto Clinico Humanitas - U.O. Ematologia

    WITHDRAWN

    Rozzano, Italy

  • Istituto Tumori Bari Giovanni Paolo II, U.O. di Ematologia e Terapia Cellulare

    RECRUITING

    Bari, Bari, Italy

  • Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico

    RECRUITING

    Sassuolo, Italy

  • Ospedale "Monsignor Raffaele Dimiccoli" - Ematologia

    RECRUITING

    Barletta, Italy

  • Ospedale Antonio Perrino - U.O. Ematologia e Trapianti di Midollo

    RECRUITING

    Brindisi, Italy

  • Ospedale Ca Foncello - S.C di Ematologia

    RECRUITING

    Treviso, Italy

  • Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.

    RECRUITING

    Bolzano, Italy

  • Ospedale Generale di zona Valduce - Oncoematologia

    RECRUITING

    Como, Italy

  • Ospedale Guglielmo da Saliceto - U.O.Ematologia

    RECRUITING

    Piacenza, Italy

  • Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda - Ematologia

    RECRUITING

    Milan, Italy

  • Ospedale S. Eugenio - UOC Ematologia

    RECRUITING

    Roma, Italy

  • Ospedale S. Martino - UOC Oncologia

    RECRUITING

    Belluno, Belluno, Italy

  • Ospedale Vito Fazzi - Ematologia

    RECRUITING

    Lecce, Italy

  • Ospedale degli Infermi di Rimini - U.O. di Ematologia

    RECRUITING

    Rimini, Italy

  • P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi

    RECRUITING

    Pescara, Italy

  • PO Sant'Elia ASP Caltanisetta - UOC Ematologia

    NOT_YET_RECRUITING

    Caltanissetta, Italy

  • Policlinico Tor Vergata - Ematologia

    NOT_YET_RECRUITING

    Roma, Italy

  • Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare

    RECRUITING

    Roma, Italy

  • Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia

    RECRUITING

    Pagani, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.